Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

5(71.4%)

Phase 1

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 3(5)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01332968Phase 3Completed

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Role: collaborator

NCT00509184Phase 2Completed

Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma

Role: collaborator

NCT00140582Phase 3Completed

Primary Rituximab and Maintenance

Role: collaborator

NCT00209209Phase 3Unknown

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Role: collaborator

NCT00954005Phase 1Terminated

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma

Role: lead

NCT00016887Phase 3Unknown

Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Role: lead

NCT00209222Phase 3Unknown

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Role: collaborator

All 7 trials loaded